datelliptium-chloride

Description: Datelliptium chloride, a ellipticine derivative, is a novel and potent DNA-intercalating agent with anti-cancer activities. Datelliptium (100 uM) shows significantly cytotoxic effects after 2 hr of treatment in suspension and primary cultures of rat hepatocytes. Datelliptium mobilizes glycogen in both rat systems in vitro concentration dependently. The half-maximal effect is 14.3 uM in isolated hepatocytes, whereas in cultured rat hepatocytes it is 5.9 uM. Datelliptium also leads to a concentration-dependent decrease in gluconeogenesis from lactate in cells1. Datelliptium acetate is selectively cytotoxic for solid tumors over leukemia L1210. Human tumors H-125 and HCT-116 demonstrates less sensitivity to datelliptium acetate. Upon intravenous administration, datelliptium acetate shows potent inhibitory activities in vivo against a variety of murine solid tumors. Datelliptium acetate is highly active against early-stage colon #38 with highest non-toxic dose (HNTD) of 170 mg/kg TD, and weight loss of 10%, T/C of 0%.

References: Toxicol In Vitro. 1992 Jul; 6(4):295-302.; Invest New Drugs. 1990 Aug; 8(3):253-61.

Related CAS : 105118-14-7 (chloride); 81531-57-9 (cation); 81531-58-0 (acetate); 157000-76-5 (chloride HCl); 958863-79-1 (mesylate)